(Multi-Specific NK Engager Antibodies)
Our fully owned, patented plug-and-play multi-specific antibody platform allows for the rapid development of multiple drug candidates. The platform has been initially validated by a pan-academic consortium and is currently further developed at our partner development and GMP manufacturing facility in Greater Boston, MA.
We are developing a proprietary tri-functional format for enhanced efficacy. We are focused on NK engager bi-specific and multi-specific antibodies for the treatment of hematological cancers and solid tumors.
Cytovia is developing NKp46 multifunctional engagers with the potential for better disease control and better safety profile.